AusCADASIL: An Australian Cohort of CADASIL

Key facts

Sponsor

Perminder Sachdev

Principal Investigator

Perminder S Sachdev, MBBS, MD, PhD, FRANZCP, FAAHMS

University of New South Wales

Enrollment

300 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2027

Study locations (5)

• John Hunter Hospital, Newcastle, New South Wales, Australia
• Prince of Wales Hospital, Sydney, New South Wales, Australia
• University of New South Wales, Sydney, New South Wales, Australia
• Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
• Royal Melbourne Hospital, Melbourne, Victoria, Australia

Collaborators

Prince of Wales Hospital, Sydney · John Hunter Hospital · St Vincent's Hospital - Sydney, Australia · Royal Brisbane and Women's Hospital · Melbourne Health · The University of Queensland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT05755997
  CERebrolysin In CADASIL
  Ever Neuro Pharma GmbH
• RECRUITINGNCT06938100
  Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASIL
  Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
• RECRUITINGNANCT06935578
  RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)
  Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
• RECRUITINGNCT05072483
  Natural History Study of CADASIL
  National Heart, Lung, and Blood Institute (NHLBI)

See all trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy →